Overview
- The study, published Aug. 26, 2026, reported that a Zika vaccine engineered with mutations in the E protein fusion loop protected mice by activating CD8+ T cells rather than by producing neutralizing antibodies.
- Antibodies from the fusion-loop mutant looked similar to normal vaccine antibodies in lab tests but failed to protect animals when transferred to unvaccinated mice, showing they did not provide passive immunity.
- When researchers transferred CD8+ T cells from vaccinated mice into unvaccinated animals those cells reduced Zika levels, and removing CD8+ T cells from vaccinated mice erased protection, proving T cells were the key protective mechanism.
- That T cell–mediated protection was short-lived: mice given the fusion-loop mutant lost protection by 12 weeks after vaccination while animals given the unmodified vaccine remained protected over the same interval.
- Authors say the result could inform 'pan-orthoflavivirus' vaccines that avoid antibody-dependent enhancement—when cross-reactive antibodies make infections worse—but they caution that making T cell memory durable and translating mouse results to humans remain major challenges.